AzTrials
AzTrials

Eating DisordersNCT00733525

Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa

A study testing Cognitive Behavioral Therapy, Fluoxetine and Guided Self-Help in people with Eating Disorders, run by University of Minnesota at 4 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will compare the medical and cost effectiveness of a stepped approach, including self-help and drug therapies, to the current best available care for bulimia nervosa. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Eating Disorders
What is being tested?
Cognitive Behavioral Therapy, Fluoxetine and Guided Self-Help
Could I receive a placebo?
No, everyone receives an active treatment
How many people
293 participants
Where
4 sitesUnited States
Study dates
Sep 2000to Aug 2005
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of bulimia nervosa

Who cannot join

  • Weight less than 85% of ideal
  • Current substance abuse or dependence
  • Pregnant
  • Currently receiving psychotherapy

Trial locations and contacts

4 sites in 1 country.

United States4 sites
  • University of North Dakota / Neuropsychiatric Research Institute

    Fargo, North Dakota, 58103

  • University of Minnesota Minneapolis, MN

    Minneapolis, Minnesota, 55455

  • Stanford University

    Palo Alto, California, 94305

  • Cornell University; White Plains, NY

    White Plains, New York, 10605

Other trials in United States

About this study

Official title: Stepped Care vs Best Available Care for Bulimia Nervosa

This study will compare the medical and cost effectiveness of a stepped approach, including self-help and drug therapies, to the current best available care for bulimia nervosa.

Read the detailed description

The eating disorder bulimia nervosa (BN) is estimated to exist in 1 % to 2 % of women from the ages of 15 to 30, and bulimic behaviors occur in many more who do not develop the disorder. Characteristic symptoms include binge eating and self-induced vomiting. Research indicates that cognitive behavioral therapy (CBT), paired with use of the antidepressant fluoxetine, is the treatment of choice for BN. However, a survey of doctoral level psychologists dealing with eating disorders found that 78% of clinicians had no training in CBT for eating disorders, with 72% also untrained in the alternative, interpersonal therapy. Self-help manuals based on CBT have been developed as a treatment option for those without access to a clinician trained in CBT for eating disorders. Studies of these manuals suggest that self-guided therapy is as effective as CBT for some individuals. Additionally, although little research has examined cost effectiveness for treatment of eating disorders, a self-help approach may be more cost effective than CBT. This study will test whether self-help therapy, in the context of a stepped treatment plan involving check-ins with a clinician and possible drug treatment, can be an effective alternative, medically and economically, to traditional CBT.

Participants at four treatment sites will be screened for diagnosis, health, and presence of other conditions through assessments in standardized questionnaires, clinical interviews, and a blood test. Participants who pass the screening will be randomly assigned to one of two treatment sequences. In the first sequence, participants will be given twenty 50-minute sessions of individual CBT treatment over 18 weeks, focusing on altering eating behaviors. If participants do not have an adequate initial response to treatment by session six, they will be offered a trial of fluoxetine in addition to their continued CBT treatment. If they do not meet response criteria at the end of the 18 weeks of CBT treatment, they will again be given the option of taking or continuing to take fluoxetine until the termination of the study. The second sequence will begin with a specially designed self-help program aimed at teaching the same skills that will be taught in CBT sessions. Participants will have nine 30-minute checkup sessions with a therapist over 18 weeks. Participants who do not respond adequately to the treatment after 10 weeks will be given the option of taking fluoxetine. Participants without sufficient recovery at the end of 18 weeks will be given the option of undergoing the first treatment sequence.

Assessments of costs and health will be made at five points: the beginning of the study, and at the study visits on Week 10, Week 18, Week 36, and Week 62. Multiple assessments will be used to test health, including eating disorder symptoms, presence of other psychopathology and personality factors, social and interpersonal functioning, and quality of life. Eating disorder symptoms will be evaluated through clinical interview, questionnaires, and weight fluctuations. Treatment variables will also be assessed, with particular interest in the measure of patient knowledge of CBT techniques, to determine how much information from the self-help manual is used and absorbed. For the cost benefit analysis, assessments will include cost of health care visits, medications, treatments, and time lost due to illness. Data on cost will be collected at study visits, except for time lost, which will be measured through a questionnaire completed by a family member once at baseline and once after 18 weeks of treatment.

Being tested
Cognitive Behavioral Therapy, Fluoxetine, Guided Self-Help
Keywords
Bulimia Nervosa
Medical subject headings
Feeding and Eating Disorders, Bulimia Nervosa

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cognitive Behavioral TherapyBehavioural

    Therapy focusing on skills needed to alter eating patterns

  • FluoxetineDrug

    Also called Prozac

    20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day

  • Guided Self-HelpBehavioural

    Manual designed to impart teachings of cognitive behavioral therapy

Study groups in NCT00733525
Study groupRoleWhat they receive
Stepped CareExperimentalParticipants will receive guided self-help with nine clinician checkups, followed by fluoxetine if nonresponsive, followed by cognitive behavioral therapy if still nonresponsive.
Receives: Behavioral: Cognitive Behavioral Therapy; Drug: Fluoxetine; Behavioral: Guided Self-Help
Cognitive Behavioral TherapyActive comparatorParticipants will receive 20 sessions of cognitive behavioral therapy with the addition of fluoxetine at interim points.
Receives: Behavioral: Cognitive Behavioral Therapy; Drug: Fluoxetine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Eating disorders examination

    Measured: Measured at baseline and Weeks 10, 18, 36, and 62

Secondary outcomes (4)
  1. Records of health care, medications, and treatments

    Measured: Measured at baseline and Weeks 10, 18, 36, and 62

  2. Height, weight, and body mass index

    Measured: Measured at baseline, Week 8, and Week 62

  3. Battery of self-report questionnaires

    Measured: Measured at baseline and Weeks 10, 18, 36, and 62

  4. Questionnaire on time lost to bulimia, completed by a family member

    Measured: Measured at baseline and after 18 weeks of treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Aug 2008 (estimated)
  2. Study startSep 2000
  3. Primary completionApr 2005
  4. Study completionAug 2005

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
293 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00733525
Sponsor's protocol ID
9802M00108
Other IDs
R01MH059304, R01MH059303, R01MH059301, R01MH059100, DSIR 83-ATAS
Status last verified
Oct 2019
First submitted
12 Aug 2008
Last updated
1 Nov 2019
Results posted
No
Data monitoring committee
Yes

Publications

  • Mitchell JE, Agras S, Crow S, Halmi K, Fairburn CG, Bryson S, Kraemer H. Stepped care and cognitive-behavioural therapy for bulimia nervosa: randomised trial. Br J Psychiatry. 2011 May;198(5):391-7. doi: 10.1192/bjp.bp.110.082172. Epub 2011 Mar 17.

    PubMed 21415046

Questions about this trial

What is this clinical trial studying?

A study testing Cognitive Behavioral Therapy, Fluoxetine and Guided Self-Help in people with Eating Disorders, run by University of Minnesota at 4 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Eating disorders examination (time frame: Measured at baseline and Weeks 10, 18, 36, and 62). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00733525, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Nov 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in